

- An observational cohort study investigated the effect of erythropoiesis-stimulating agent (ESA) switching among 785 adult patients with chronic kidney disease receiving hemodialysis at 42 centers in 7 European countries.
- Hemoglobin concentration (Hb) and ESA doses over time were evaluated, as well as ESA dose ratio at switch from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) for anemia management.
- Mean achieved Hb was maintained within a narrow range over the 6-month post-switch observation period, with mean monthly Hb well within the target range of 10–12 g/dL at all time points.
- Correspondence between mean Hb and mean DA dose indicated that physicians titrated DA doses to achieve Hb concentrations comparable to those attained with PEG-Epo before switching.
- Despite wide variation in dose ratio at the time of switch, mean DA dose and achieved Hb converged within narrow ranges by Month 6 post-switch (23.9–27.0 $\mu\text{g}/\text{week}$ and 11.1–11.5 g/dL, respectively, across dose-ratio categories of <0.8, 0.8–1.2, and >1.2).

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Amgen (Europe) GmbH, Zug, Switzerland. Medical writing assistance for this study was provided by W. Mark Roberts, Montreal, Canada. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).